

Special Issue

Advances in Chronic Lymphocytic Leukaemia (CLL) Research

Message from the Guest Editor

Research activity in various aspects of CLL, including aetiology, the biology of the malignant cells, IGHV mutational status and gene usage, chromosomal and molecular aberrations, roles of flow cytometry and molecular investigations in defining complete remissions, and treatment strategies, including use of more targeted therapies and novel agents. It seems timely to review progress towards answering questions raised by the original papers and whether these have provided a better understanding of the aetiology of CLL, whether pathogenic- or auto-antibodies are pivotal in initiation of the oncogenic transformation of normal B cells, and, most importantly, progress towards improved survival and a potential cure. To mark the approaching 25th anniversary in 2024, *Cancers* (IF 6.575) now publish a Special Issue on CLL and invited me to act as . Original research and review are welcome.

Guest Editor

Prof. Dr. H. Denis Alexander

Personalised Medicine Centre, School of Medicine, Ulster University, C-TRIC Building, Altnagelvin Hospital, Derry/Londonderry BT47 6SB, Northern Ireland, UK

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/132833

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)